EASL Liver Cancer Summit | Professor Abdel Ghani Atef: FibroScan Aids in Early Screening of Liver Cancer

EASL Liver Cancer Summit | Professor Abdel Ghani Atef: FibroScan Aids in Early Screening of Liver Cancer

2025.03.04
Hepatocellular carcinoma (HCC), the most common primary malignant liver tumor, is one of the leading causes of death in patients with cirrhosis. Non-invasive diagnostic tools such as transient elastography (FibroScan) have shown great promise in identifying patients at high risk of HCC. Recently, the 2025 EASL Liver Cancer Summit was held in Paris, France. Professor Abdel Ghani Atef from the Damas Liver & G.I.T Center in Egypt presented research on the value of ultrasound elastography in the early detection of HCC in patients with cirrhosis. To this end, a journalist from Oncology Frontier traveled to the summit and invited Professor Abdel Ghani Atef to have an in-depth discussion on topics such as the role of FibroScan in HCC screening and the significance of liver stiffness measurement cutoff values.
BOC/BOA 2024 | Professor Zhixiang Shen: Strengthening Innovation and Integrating Breakthroughs into Clinical Practice

BOC/BOA 2024 | Professor Zhixiang Shen: Strengthening Innovation and Integrating Breakthroughs into Clinical Practice

2025.03.03
From July 5th to 7th, the 2024 Annual Progress Seminar in Clinical Oncology in China (BOC) and Best of ASCO 2024 China (BOC/BOA 2024) were grandly held in Guangzhou. The conference gathered domestic oncology experts and related professionals to witness the past year's research progress in clinical oncology in China and discuss the future innovative development path of clinical oncology in China. "Oncology Frontier - Hematology Frontier" invited renowned expert in the field of hematologic oncology, Professor Zhixiang Shen from Ruijin Hospital, Shanghai JiaoTong University School of Medicine, for an interview. He introduced major research advancements in hematologic oncology and shared his profound insights on innovation translation and the importance of integrating innovative results into clinical practice.
BOC/BOA 2024 | Professor Donglu Zhao: Annual Progress in the Field of Hematologic Oncology in China

BOC/BOA 2024 | Professor Donglu Zhao: Annual Progress in the Field of Hematologic Oncology in China

2025.03.03
From July 5th to 7th, the "2024 Annual Progress Seminar in Clinical Oncology in China (BOC)," hosted by the Chinese Society of Clinical Oncology (CSCO), was held in Guangzhou. The conference invited numerous domestic oncology experts to highlight the "2023 Annual Progress in Clinical Oncology in China" selected by CSCO. Additionally, it focused on the theme of the 2024 ASCO Annual Meeting, "The Art and Science of Cancer Care: From Comfort to Cure," and discussed and interpreted major research presented at ASCO. To gain in-depth insights into the relevant content and trends, "Oncology Frontier - Hematology Frontier" conducted an exclusive interview with Professor Donglu Zhao from the Harbin Institute of Hematology and Oncology, who provided an excellent analysis of these topics.
Focus on Annual Advances in Clinical Oncology Research in the Field of Breast Cancer in China, Multidisciplinary Collaboration Boosts New Drug

Focus on Annual Advances in Clinical Oncology Research in the Field of Breast Cancer in China, Multidisciplinary Collaboration Boosts New Drug

2025.03.03
From July 5-7, 2024, the 2024 China Annual Clinical Oncology Advances Symposium (BOC) and Beast of ASCO® 2024 China (BOC/BOA) were grandly held in Guangzhou. In the field of breast cancer, this conference brought together important research from the Chinese breast cancer field in 2023 and highlighted key advancements from the American Society of Clinical Oncology (ASCO) Annual Meeting. As one of the contributors to the "Annual Advances in Clinical Oncology Research in China," Professor Biyun Wang from Fudan University Shanghai Cancer Center also detailed the ACE-Breast-02 study at this conference, showcasing the rigor and innovation of Chinese research. "Oncology Frontier" interviewed Professor Biyun Wang, and the compilation is presented below.